Cavernous Malformation Research
Our research page features detailed studies of cavernous malformation (CM) conducted in various formats. Research is the critical foundation towards a cure for CM. The discovery of new information and novel understanding of the science behind CM also generates an improved quality of life for patients. As scientists strive to answer the important questions through systematic investigation, new pathways of discovery are unleashed.
Focused ultrasound-microbubble treatment arrests the growth and formation of cerebral cavernous malformations by Delaney G. Fisher et al (2025)
Focused ultrasound-microbubble (FUS-MS) shows promise in animal studies; anticipating clinical trial studies to prove efficacy and safety with respect to a treatment alternative for CCM.
Surgical outcomes and natural history of intramedullary spinal cord cavernous malformations: a single-center series and meta-analysis of individual patient data by Jetan H. Badhiwala et al (2014)
Provides a review and meta-analysis of literature on the natural history of intramedullary spinal cord cavernous malformations and patient outcomes after surgery.
Mild hypoxia could impact CCM, promoting lesion growth based on mouse models.
Discusses existing and potential future treatment options, focusing on both surgical and emerging pharmacological approaches.
Interrogating the ccm-3 Gene Network by Brent Derry et al (2018)
Examination of the CCM3 genetic mutation.
How inflammation may contribute to CCM, exploring the molecular and cellular mechanisms involved.
Explores the link between female hormone therapy and increased risk of brain hemorrhage in women with CCM.
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations: a phase 1/2a, randomized placebo-controlled trial by Issam A. Awad et al (2025)
Assesses the safety and efficacy of atorvastatin on rebleeding in patients with CCMs after a symptomatic hemorrhage.
Familial Cerebral Cavernous Malformations by Kelly D. Flemming et al (2023)
Discusses CCMs including genetics, symptoms, diagnosis, and management.
Discusses somatic mutations which cause individual lesions, and interactions between mutations.
Provides an overview of CCMs including epidemiology, clinical presentation, diagnosis via MRI, management strategies and prognosis.
Blocking Signalopathic Events to Treat Cerebral Cavernous Malformations by Salim Adbelilah-Seyfried et al (2020)
Discusses findings in mouse models which suggests possible avenues for drug treatments related to CCM.
Low 25-hydroxy-vitamin D levels are more common in patients with CM presenting with hemorrhage.
Having lower vitamin D and non-HDL cholesterol levels is linked to increased severity in CCM.